In fact, nuclear palisading and perivascular hyalinization are seen in up to 33% of GISTs
A total of 946 patients with advanced and/or metastatic KIT-positive GIST
received either a 400 or 800 mg dose of Glivec per day (400 mg twice daily).
are usually centered in the bowel wall but may extend to involve either the mucosal or the serosal surfaces.
In addition to leiomyosarcoma, 10% to 47% of GISTs
show expression of SMA.
9] Hence, the features of FLSs cannot be specific to GISTs
but could be of interest if we consider the causality of FLS collagen fibrils and GISTs
or the possibility of GISTs
producing such collagen.
The approval for this new indication is based on data from a National Cancer Institute-sponsored Phase III study that showed a dramatic reduction in the return of GIST
after surgery in patients treated for about one year with Gleevec versus placebo.
Microscopically, the benign GISTs
(leiomyoma) were composed of spindle cells with pale or eosinophilic fibrillar cytoplasm.
Trials have evaluated alternative treatments for imatinib-resistant GIST
, whether early or late.
The effectiveness of Gleevec in GIST
is based on objective response rate.
are the most common malignant form of sarcoma that arise in the gastrointestinal tract, predominantly affecting people between 30 - 60 years of age.
The tumor suppressor protein PTEN was intact (positive expression) in the majority of GISTs
, including 88% (15/17) of D-WT and 100% (20/20) of TKI-R GISTs
The discovery of oncogenic KIT kinase mutations in GISTs
and the introduction of kinase inhibitor therapies have led to a rapid evolution in the understanding of these tumors.
After identification of activating mutations in the coding sequence of KIT as the pathogenetic mechanism underlying most GISTs
, (2) and the concurrent availability of the ABL/KIT/PDGFR kinase inhibitor imatinib mesylate in early clinical trials for chronic myelogenous leukemia, (3) Joensuu et al (4) demonstrated for the first time the activity of this compound in a solid tumor.
We present a case of recurrent gastrointestinal (GI) bleeding from multiple GISTs
in a patient with NF1.
For those patients whose GIST
does return, this can be devastating both physically and emotionally, even though Glivec can manage recurring GISTs